Earnings
Myriad Genetics Raises Revenue Outlook Midpoint To Sell Prenatal Unit For $210 Million
Myriad is selling its prenatal business to Labcorp and narrowing to cancer care, while its third-quarter loss widened to $43.9 million.
MYGN
Myriad Genetics (MYGN) news from Bullished: SEC filings, earnings, insider trades and deals, explained in plain English with links to the source documents.
Earnings
Myriad Says Denied Claims, Not Lower Contract Rates, Are Dragging Down Hereditary Cancer Test Revenue
The CFO said revenue per test fell because payers pay nothing on more claims, even as Myriad agreed to sell its prenatal unit for $210 million.
Deals
Myriad Genetics Agrees To Sell Prenatal Testing Business To Labcorp For $210 Million In Cash
Labcorp expects the business to add approximately $160 million in first-year revenue; closing is targeted for early 2027.
SEC Filings
Myriad Genetics Will Pay Former Commercial Chief Brian Donnelly $1,322,294 In Severance, 8-K Shows
The payout comes with two years of equity vesting treatment and takes effect October 14 unless Donnelly revokes the agreement.